NMPA-style approved bird nucleotide cyclase agonist makes Zeshu ® (Linalopeptide) listed in China

recently, AstraZeneca(http:// announcedthat the NationalDrug(http://Regulatory Authority (NMPA) has officially approved the listing of the world's first (First in class) bird in-class bird nucleotide cyclotheragosis agonist,® Linalo peptide, in Chinaon linalotidelinalotide is a bird nucleotide cyclosise-C agonist, a
new drug(http://recommended by the American Society of Digestive Diseases (AGA) guidelines for treating constipation-type irritability syndrome (IBS-C), and is also the standarddrug(
http:// recommended level: strong, evidence level: high) recommended for the treatment of IBS-CChina Phase III ClinicalTrial(http:// confirmed that linalotide significantly alleviated IBS-C-related symptoms compared to the placebo group, and that the remission response was more than twice that of the placebo group (31.7 percent vs 15.4%), and that the effect was reflected in the first week of treatment and the symptoms improved throughout the treatment In addition, since linalotide acts on the intestinal part and is almost non-absorbed into the blood, it is safer Studies have shown that the most common adverse reactions to linalotide are mild and moderate diarrhea, with no clinically significant sequelae the innovative mechanism of making Zeshu ®
make Zeshu ® is to activate a kind of bird nucleotide cyclase of the human body, promote intestinal fluid secretion, and achieve the effect of reducing the high sensitivity of the internal organs to alleviate the symptoms of abdominal pain, bloating and constipation in patients with constipation-type irritable bowel syndrome at the same time compared with placebo, more than 60% of patients were able to achieve autonomous defecation after one day of use, within a week, the patient's severe abdominal pain symptoms and the frequency of fully autonomous defecation improved significantly, and nearly 90% of patients had significantly increased the number of self-defecation softens throughout the treatment cycle, and nearly 80% of patients had significantly improved abdominal pain and bloating